Gout Is Prevalent but Under-Registered Among Patients With Cardiovascular Events: A Field Study
Irene Calabuig1, Miguel Gómez-Garberí2, Mariano Andrés1,2
1Sección de Reumatología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain.
Insights
Gout is highly prevalent in hospitalized cardiovascular disease patients, affecting 15%. Many cases go undiagnosed and undertreated, highlighting a critical gap in managing this independent cardiovascular risk factor.
Area of Science:
- Cardiology
- Rheumatology
- Epidemiology
Background:
- Gout is a significant independent risk factor for cardiovascular (CV) disease, contributing to morbidity and mortality.
- Understanding gout's prevalence and management in hospitalized CV patients is crucial but currently undefined.
Purpose of the Study:
- To determine the prevalence, characteristics, and management of gout in patients hospitalized for cardiovascular events.
- To identify predictors of gout in this specific patient population.
Main Methods:
- An observational, descriptive, cross-sectional study involving 266 patients admitted for CV events.
- Gout diagnosis confirmed using 2015 ACR/EULAR criteria; data collected via interviews and medical records.
- Multivariate logistic regression used to identify predictors of gout.
Main Results:
- Gout prevalence was 15.0% (40/266 patients), with diagnosis absent in 35% of records and under-registration in discharge reports.
- Independent predictors for gout included prior hyperuricemia (OR 2.9) and chronic kidney disease (OR 3.0).
- Only 50% of gout patients received urate-lowering therapy upon admission, with suboptimal serum urate control.
Conclusions:
- Gout is highly prevalent in hospitalized cardiovascular patients, indicating significant under-recognition.
- Suboptimal management of gout in this population necessitates improved awareness and treatment strategies.
- Addressing gout in CV patients is essential for mitigating cardiovascular risk.
Abstract:
Objectives: Gout is an independent cardiovascular (CV) risk factor with significant morbidity and mortality. We aimed to estimate the prevalence of gout, characteristics and management in a hospitalized population for CV disease, a topic that remains to be defined. Methods: An observational, descriptive, cross-sectional study was carried out in patients admitted for CV events in the Cardiology, Neurology, and Vascular Surgery units of a tertiary center. Patients were selected following a non-consecutive, systematic sampling. Data about CV disease and gout were obtained from face-to-face interviews and patients' records. Gout diagnosis was established using the 2015 ACR/EULAR clinical classification criteria. The registration rate of gout was assessed by auditing patients' records and hospital discharge reports of CV events from the units of interest in the previous 2 years. To predict the presence of gout, multivariate logistic regression models were built to study the possible explanatory variables. Results: Two hundred and sixty six participants were recruited, predominantly males (69.9%) and Caucasians (96.6%) with a mean age of 68 years. Gout was identified in 40 individuals; thus, the prevalence was 15.0% (95% CI 10.9-19.2%). In 35% of cases, the diagnosis was absent from patients' records. Gout was found in 1.4-2.6% of hospital discharge reports of CV events, also indicating under-registration. The disease was long-standing, but with low reported rates of flares, involved joints, and tophi. At admission, only half of the gout patients were on urate-lowering therapy, being 38.5% of them on serum urate <6 mg/dl. The only independent predictor of gout was the existence of previous hyperuricemia (median serum urate in previous 5 years ≥7 mg/dl), with an odds ratio of 2.9 (95% CI 1.2-7.1); if hyperuricemia is not included in the model, the only independent predictor was chronic kidney disease (odds ratio 3.0; 95% CI 1.4-6.6). Conclusion: Gout is highly prevalent among patients admitted for CV events, with significant lack of awareness and suboptimal management, despite being a well-established independent CV risk factor.
More Related Videos
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Hypertension III: Clinical Manifestations and Diagnostic Studies
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...


